INTRODUCTION: Obesity is a major risk factor for the development of endometrial cancer (EC). An improved understanding of biologic mechanisms associated with weight loss, including alteration in inflammation, hormonal balance, and cancer antigens expression may lead to the development of effective cancer prevention strategies. The goal of this study was to explore longitudinal biomarker changes in obese women who underwentweight loss intervention, testing the hypothesis biomarker levels can be altered through intentional weight loss. METHODS: Serum samples from 89 participants with Class II and Class III obesity and 43 non morbidly obese comparisons were obtained in Re-Energize with Nutrition, Exercise and Weight Loss (RENEW) study as previously reported. Twenty-one bead-based xMAP immunoassays were utilized, including cancer-associated antigens, cytokines, chemokines, and hormones. One-way repeated measures ANOVA was used to examine the association between changes in biomarker expression levels over time (baseline, 6 months and 12 months). Linear mixed effects models were used to examine longitudinal relationships between biomarker expression levels. RESULTS:Mean levels of VEGF, soluble E-selectin, GH, adiponectin, IL-6, IL-7, CA-125, and IGFBP-1 significantly differed between time periods. In adjusted mixed linear models, decreasing BMI was significantly associated with lower levels of soluble E-selectin and IL-6 and increases in GH, adiponectin, and IGFBP-1. CONCLUSIONS: This is one of the first efforts to explore changes in cancer-associated biomarkers in a cohort of weight loss research participants at high risk for EC development. Our findings demonstrate that changes in the expression of markers can be achieved with weight loss intervention. Copyright Â
RCT Entities:
INTRODUCTION:Obesity is a major risk factor for the development of endometrial cancer (EC). An improved understanding of biologic mechanisms associated with weight loss, including alteration in inflammation, hormonal balance, and cancer antigens expression may lead to the development of effective cancer prevention strategies. The goal of this study was to explore longitudinal biomarker changes in obesewomen who underwent weight loss intervention, testing the hypothesis biomarker levels can be altered through intentional weight loss. METHODS: Serum samples from 89 participants with Class II and Class III obesity and 43 non morbidly obese comparisons were obtained in Re-Energize with Nutrition, Exercise and Weight Loss (RENEW) study as previously reported. Twenty-one bead-based xMAP immunoassays were utilized, including cancer-associated antigens, cytokines, chemokines, and hormones. One-way repeated measures ANOVA was used to examine the association between changes in biomarker expression levels over time (baseline, 6 months and 12 months). Linear mixed effects models were used to examine longitudinal relationships between biomarker expression levels. RESULTS: Mean levels of VEGF, soluble E-selectin, GH, adiponectin, IL-6, IL-7, CA-125, and IGFBP-1 significantly differed between time periods. In adjusted mixed linear models, decreasing BMI was significantly associated with lower levels of soluble E-selectin and IL-6 and increases in GH, adiponectin, and IGFBP-1. CONCLUSIONS: This is one of the first efforts to explore changes in cancer-associated biomarkers in a cohort of weight loss research participants at high risk for EC development. Our findings demonstrate that changes in the expression of markers can be achieved with weight loss intervention. Copyright Â
Authors: Faina Linkov; Alex Lisovich; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; Brian Nolen; Matthew Winans; William Bigbee; Jill Siegfried; Anna Lokshin; Robert L Ferris Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-01 Impact factor: 4.254
Authors: Efstathios V Kotidis; George G Koliakos; Vasilios G Baltzopoulos; Konstantinos N Ioannidis; John G Yovos; Spiros T Papavramidis Journal: Obes Surg Date: 2006-11 Impact factor: 4.129
Authors: Xiaochen Zhang; Jennifer Rhoades; Bette J Caan; David E Cohn; Ritu Salani; Sabrena Noria; Adrian A Suarez; Electra D Paskett; Ashley S Felix Journal: Int J Gynecol Cancer Date: 2019-08-26 Impact factor: 3.437
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Faina Linkov; Lora E Burke; Marina Komaroff; Robert P Edwards; Anna Lokshin; Mindi A Styn; Eugene Tseytlin; Kyle E Freese; Dana H Bovbjerg Journal: Gynecol Oncol Date: 2014-01-22 Impact factor: 5.482
Authors: Ashley F Haggerty; Sarah Huepenbecker; David B Sarwer; Jacqueline Spitzer; Greer Raggio; Christina S Chu; Emily Ko; Kelly C Allison Journal: Gynecol Oncol Date: 2015-11-28 Impact factor: 5.482
Authors: Faina Linkov; Sharon L Goughnour; Shalkar Adambekov; Anna Lokshin; Joseph L Kelley; Paniti Sukumvanich; John T Comerci; Kacey G Marra; Lauren E Kokai; J Peter Rubin; Anda M Vlad; Brian J Philips; Robert P Edwards Journal: Biomark Med Date: 2018-07-25 Impact factor: 2.851
Authors: Alberto A Mendivil; Mark A Rettenmaier; Lisa N Abaid; John V Brown; John P Micha; Katrina L Lopez; Bram H Goldstein Journal: JSLS Date: 2015 Jan-Mar Impact factor: 2.172